GlobeStar Therapeutics (GlobeStar Therapeutics) Debt-to-Equity : -0.24 (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is GlobeStar Therapeutics Debt-to-Equity?

GlobeStar Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.37 Mil. GlobeStar Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. GlobeStar Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-1.53 Mil. GlobeStar Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was -0.24.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for GlobeStar Therapeutics's Debt-to-Equity or its related term are showing as below:

GSTC' s Debt-to-Equity Range Over the Past 10 Years
Min: -3.19 Med: -0.24 Max: 8.46
Current: -0.24

During the past 13 years, the highest Debt-to-Equity Ratio of GlobeStar Therapeutics was 8.46. The lowest was -3.19. And the median was -0.24.

GSTC's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs GSTC: -0.24

GlobeStar Therapeutics Debt-to-Equity Historical Data

The historical data trend for GlobeStar Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlobeStar Therapeutics Debt-to-Equity Chart

GlobeStar Therapeutics Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Debt-to-Equity

Get a 7-Day Free Trial

-0.17

-0.24

-0.03

-0.02

-0.25

GlobeStar Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															-0.02	-	-0.01	-0.25	-0.24

Competitive Comparison of GlobeStar Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, GlobeStar Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GlobeStar Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlobeStar Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where GlobeStar Therapeutics's Debt-to-Equity falls into.

GlobeStar Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

GlobeStar Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.36	+	0)	/	-1.434
	=	-0.25

GlobeStar Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.369	+	0)	/	-1.533
	=	-0.24

GlobeStar Therapeutics (OTCPK:GSTC) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

GlobeStar Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of GlobeStar Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

GlobeStar Therapeutics (GlobeStar Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlobeStar Therapeutics Corp (OTCPK:GSTC) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

719 Jadewin Avenue, Richland, WA, USA, 99352

Website

https://www.globestarthera.com

GlobeStar Therapeutics Corp is a clinical-stage Pharmaceutical Company introducing a patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. The company is focused on developing therapies for people with serious and life-threatening rare disorders.

Executives

James C Katzaroff	director, officer: CEO	719 JADWIN AVE., RICHLAND WA 99352
William J Farley	director	468 ALBERN AVE, OCEANSIDE NY 11572
Robert Chicoski	officer: CFO	145 NEWTON ROAD, HAVERHILL MA 01830
Alex K Blankenship	director, officer: CEO, Pres., Secr., Treas.	14001 WALDEN RD., SUITE 600, MONTGOMERY TX 77356
Brent Atwood	10 percent owner	5000 RIVERSIDE DR STE100E, IRVING TX 75039
Bruce C Badeau	director	770 S. POST OAK LN., STE. 360, HOUSTON TX 77056
Robert W Fryer	director	1520 ENCLAVE, # 1208, HOUSTON TX 77077
Robert Federowicz	director, officer: Interim CEO & Chairman	495 GRAND BLVD., SUITE 206, MIRAMAR BEACH FL 32550